Innovation
DETERA Therapeutics, a peptide to prevent crescentic glomerulonephritis (CGN)
… enable the 10,000 patients in Europe and America to protect their kidney function, as current standard treatments are still not effective enough. In October 2024, three … DETERA is currently securing funding to support all of its projects. It has already raised public money through …
Published on: